Eli Lilly's Strategic Expansion: A Dual Catalyst for Growth

Eli Lilly surges on swift FDA approval for weight-loss drug Foundayo and a major $7.8 billion acquisition of Centessa Pharmaceuticals, expanding its pipeline.

Eli Lilly & Co. has delivered a powerful one-two punch to the market, unveiling two major strategic developments within a 48-hour window. The pharmaceutical giant's shares responded positively, climbing more than four percent on the back of a multi-billion dollar acquisition and a record-setting regulatory approval.

A Landmark FDA Green Light

In a move that underscores its operational momentum, Eli Lilly received U.S. Food and Drug Administration (FDA) approval for its oral weight management drug, Orforglipron, to be marketed as Foundayo. The approval process was remarkably swift, concluding a mere 50 days after submission—a full 294 days ahead of the standard review deadline. This marks the fastest approval for a novel molecule since 2002 and represents the first authorization under the FDA's new voucher program for nationally prioritized therapies.

Foundayo, a small-molecule GLP-1 medication, offers a practical dosing advantage as it can be taken without restrictions, unlike some injectable or specific oral competitors. The drug is scheduled to begin shipping through LillyDirect on April 6, with broader availability in U.S. pharmacies to follow shortly after. The listed price starts at $149 per month for self-pay patients, though the cost could drop to as low as $25 for those with insurance coverage. Analysts note that Novo Nordisk, with its competing oral therapy approved in December, has established an early market presence that may initially challenge Foundayo's penetration.

Bolstering the Pipeline Through Acquisition

Concurrently, the company announced its agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion. The deal, priced at $38 per share, represents a 38% premium over Centessa's closing price on Monday. The transaction includes potential additional milestone payments of up to $1.5 billion contingent upon successful FDA approval of a key asset.

This acquisition represents Eli Lilly's third full takeover this year and its fourth within the past twelve months. The strategic buying spree is largely fueled by the substantial revenue generated by its blockbuster GLP-1 drugs, Mounjaro and Zepbound, which together brought in $36.5 billion in 2025.

Centessa's core asset is its portfolio of Orexin Receptor-2 agonists, designed to treat conditions such as excessive daytime sleepiness, narcolepsy, and idiopathic hypersomnia. The lead candidate, cleminorexton, has demonstrated promising results across multiple indications in Phase IIa studies. Market experts, including Oppenheimer analyst Kostas Biliouris, estimate the potential market for Orexin agonists could reach $15 to $20 billion, assuming approximately a quarter of eligible patients seek treatment. The addressable market could expand significantly if applications broaden to include conditions like Alzheimer's or depression.

Broadening the Foundation for Future Growth

Citi analysts reacted favorably to the Centessa deal, highlighting the "large collective market potential across the three indications." The transaction is expected to close in the third quarter of this year.

This move directly addresses a recurring topic among investors: diversifying the company's revenue streams beyond its heavy reliance on GLP-1 therapies. By aggressively entering the sleep medicine, neuroscience, and gene-editing technology sectors, Eli Lilly has substantially widened its development pipeline in a short period. The market will gain further insight into the company's trajectory when it reports its next quarterly earnings on April 30; analysts are forecasting earnings per share of $7.36.